Reliance Industries Limited (RIL), led by Mukesh Ambani, has acquired Karkinos Healthcare, a technology-driven oncology-focused platform, for ₹375 crore. The acquisition was executed through RIL’s wholly-owned subsidiary, Reliance Strategic Business Ventures Limited (RSBVL), which subscribed to shares and debentures of Karkinos as part of the transaction.
RSBVL subscribed to:
The deal was finalised on December 27, 2024, and Karkinos cancelled 30,075 equity shares held by previous shareholders under an approved resolution plan.
Incorporated on July 24, 2020, Karkinos specialises in early cancer detection, diagnosis, and management using advanced technology. The company aims to make cancer care more affordable while maintaining profitability.
Key highlights:
Karkinos’ past investors include Ewart Investments (Tata Sons subsidiary), Reliance Digital Health, Mayo Clinic (US), Sundar Raman, and Ravi Kant (ex-MD of Tata Motors).
This acquisition aligns with RIL’s plan to expand its healthcare portfolio, offering affordable cancer care services across India.
The National Company Law Tribunal (NCLT), Mumbai, approved RSBVL’s resolution plan under the Corporate Insolvency Resolution Process. The deal required no additional regulatory clearances.
The acquisition marks a significant step in RIL’s diversification into healthcare services.
Reliance Industries Limited is a major Indian multinational company based in Mumbai, Maharashtra. It operates in various sectors, including energy, petrochemicals, natural gas, retail, entertainment, telecommunications, media, and textiles.
Reliance Industries share price is trading at ₹1,220.25, reflecting a slight dip of ₹0.80 (0.066%) as of 9:50 AM on December 30. The stock opened at ₹1,216.40 and reached a high of ₹1,220.75 and a low of ₹1,214.15 during the session. With a market capitalisation of ₹16.51 lakh crore, Reliance Industries has a price-to-earnings (P/E) ratio of 24.32 and a dividend yield of 0.41%. Over the past year, the stock has touched a 52-week high of ₹1,608.80 and a 52-week low of ₹1,201.50.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in securities market are subject to market risks, read all the related documents carefully before investing.
Published on: Dec 30, 2024, 9:55 AM IST
We're Live on WhatsApp! Join our channel for market insights & updates